# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and maintains $37 p...
The Company expects adjusted EBITDA for 2024 to be $25 to $30 million, up over 75% at the midpoint, representing an adjusted EB...
Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced ...
Anika Therapeutics (NASDAQ:ANIK) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $(...
Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and raises the pric...
Stephens & Co. analyst George Sellers reiterates Anika Therapeutics (NASDAQ:ANIK) with a Equal-Weight and maintains $22 ...
Anika Therapeutics (NASDAQ:ANIK) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(...
Fiscal 2024 GuidanceIn 2024, Anika is prioritizing accelerated growth in profitability, with a focus on the products with the g...